The value and distribution of high-density lipoprotein subclass in patients with acute coronary syndrome

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Tian, Li ^a   Li, Chuanwei ^a   Liu, Yinghui ^a   Chen, Yucheng ^a   Fu, Mingde ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; ECG ABNORMALITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOBLOTTING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN LOCALIZATION; STABLE ANGINA PECTORIS; SYMPTOM; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ACUTE CORONARY SYNDROME; AGED; APOLIPOPROTEINS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED;

EID: 84899882784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085114     Document Type: Article

References (26)

1. Sacks FM, Expert Group on HDL cholesterol (2002) The role of high density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 15:139-143.
2. Ballantyne CM, Herd JA, Ferlic LL, Kay Dunn J, Farmer JA, et al.(1999) Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99:736-743. (Pubitemid 29083012)
3. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 341:410-418. (Pubitemid 29362514)
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278.
5. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20:1253-1268. (Pubitemid 39120790)
6. Hausenloy DJ, Yellon DM (2008) Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 94:706-714. (Pubitemid 351744686)
7. Al-Rasadi K, Al-Zakwani I, Zubaid M, Ali A, Bahnacy Y, et al. (2011) Prevalence, Predictors, and impact of low high-density lipoprotein cholesterol on in-hospital outcomes among acute coronary syndrome patients in the Middle East. Open Cardiovasc Med J 5:203-209.
8. Chenevard R, Hürlimann D, Spidker L, Béchir, Enseleit F, et al. (2012) Reconstituted HDL in Acute Coronary syndromes. Cardiovasc Ther 30:e51-e57.
9. von Eckardstein A, Nofer JR, Assmann G (2001) High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Tromb Vasc Biol 21:13-27.
10. Wu XW, Fu MD, Liu BW (1999) Study on the immunodetection method of HDL subclasses in human serum. Chin J Arterioscler 7:253-255.
11. Xu YH, Fu MD (2003) Alterations of HDL subclasses in hyperlipidemia. Clin Chim Acta 332:95-102.
12. Kontush A, Chapman MJ (2006) Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3:144-153.
13. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, et al. (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24:2181-2187. (Pubitemid 39482449)
14. Cheung MC, Brown BG, Wolf AC (1991) Altered particle size distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease. J lipid Res 32:383-394.
15. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med 352:1685-1695.
16. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2006) Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2:504-511. (Pubitemid 44353291)
17. Ansell BM, Navab M, Hama S, Kamranpour N, Fonarow G, et al. (2003) Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108:2751-2756. (Pubitemid 37498976)
18. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, et al. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:1495-1504.
19. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711-1718. (Pubitemid 32259905)
20. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, et al. (2005) High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 26:890-896. (Pubitemid 40676569)
21. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, et al. (2000) The TIMI risk score for unstable angina/non-ST elevation MI:a method for prognostication and therapeutic decision making. JAMA 284:835-842. (Pubitemid 30643610)
22. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, et al. (2003) Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163:2345-2353. (Pubitemid 37310196)
23. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD (1998) Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 18:1723-1729. (Pubitemid 28521061)
24. Hesler CB, Swenson TL, Tall AR (1987) Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem 262:2275-2282. (Pubitemid 17102658)
25. Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P, et al. (2005) Compromised LCAT function is associated with increased atherosclerosis. Circulation 112:879-884. (Pubitemid 41170075)
26. Borggreve SE, De Vries R, Dullaart RP (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33:1051-1069. (Pubitemid 38019139)